Literature DB >> 29864623

MiR-214 promotes cell meastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway.

Qiao Guanen1, Shi Junjie2, Wu Baolin3, Wang Chaoyang4, Yang Yajuan5, Li Jing5, Li Junpeng2, Ning Gaili6, Wang Zhongping7, Wang Jun5.   

Abstract

There is growing evidence shown that microRNAs (miRNAs) are associated with cancer and can play a role in human cancers as oncogenes or tumor suppressor genes. MicroRNA-214 (miR-214) shows carcinogenesis in various tumor types, but little is known about biological functions of miR-214 in esophageal squamous cell carcinoma (ESCC). In this study, we observe that the expression of miR-214 is not only increased in human ESCC tissues, but also remarkably increased in cell lines correlates with LZTS1. In addition, the expression of miR-214 inhibited proliferation of ESCC cells in vitro and inhibit the growth of xenograft tumor in vivo. The results show miR-214 serve as a tumor promoter regulating cells migration, invasion and apoptosis in ESCC. Ferthermore, LZTS1 has been proved to as a functional target for miR-214 to regulate cells poliferation and apoptosis. In summary, these results suggest that miR-214 serves as tumor promoter to promote proliferation, migration, invasion and inhibit apoptosis of ESCC cells by targeting LZTS1 via PI3K/AKT/mTOR signaling pathway. The miR-214/LZTS1 pathway provides a new insight into the molecular mechanisms that the occurrence and development of ESCC and it provides a novel therapeutic target for ESCC.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; ESCC; Meastasis; MiR-214; PI3K/AKT/mTOR pathway

Mesh:

Substances:

Year:  2018        PMID: 29864623     DOI: 10.1016/j.biopha.2018.05.149

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022

2.  MiR-762 regulates the activation of PI3K/AKT and Hippo pathways involved in the development of gastric cancer by targeting LZTS1.

Authors:  Kuaiyun Yu; Heng Zhu
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

3.  miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma.

Authors:  Jianfeng Xu; Haiyan Lv; Bo Zhang; Feng Xu; Hongyu Zhu; Baofu Chen; Chengchu Zhu; Jianfei Shen
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

4.  circ_NRIP1 is oncogenic in malignant development of esophageal squamous cell carcinoma (ESCC) via miR-595/SEMA4D axis and PI3K/AKT pathway.

Authors:  Shifan Zhou; Zhizhong Guo; Chaofeng Zhou; Yu Zhang; Sai Wang
Journal:  Cancer Cell Int       Date:  2021-05-06       Impact factor: 5.722

5.  MicroRNA-2053 involves in the progression of esophageal cancer by targeting KIF3C.

Authors:  Wenjian Yao; Xiangbo Jia; Lei Xu; Saisai Li; Li Wei
Journal:  Cell Cycle       Date:  2021-05-31       Impact factor: 5.173

6.  Sinomenine sensitizes human gastric cancer cells to cisplatin through negative regulation of PI3K/AKT/Wnt signaling pathway.

Authors:  Ying Liu; Changqing Liu; Ting Tan; Shang Li; Shunyu Tang; Xingyin Chen
Journal:  Anticancer Drugs       Date:  2019-11       Impact factor: 2.248

7.  Identification of miRNAs and genes for predicting Barrett's esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis.

Authors:  Chengjiao Yao; Yilin Li; Lihong Luo; Qin Xiong; Xiaowu Zhong; Fengjiao Xie; Peimin Feng
Journal:  PLoS One       Date:  2021-11-24       Impact factor: 3.240

Review 8.  A Systematic Review Exploring the Anticancer Activity and Mechanisms of Glucomannan.

Authors:  Jun-Yi Li; Fei Sun; Hai-Feng Zhou; Jia Yang; Cong Huang; Heng Fan
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810

9.  Rap1A promotes esophageal squamous cell carcinoma metastasis through the AKT signaling pathway.

Authors:  Qinfang Li; Aiping Xu; Yuan Chu; Tao Chen; Hongqi Li; Liqing Yao; Pinghong Zhou; Meidong Xu
Journal:  Oncol Rep       Date:  2019-09-12       Impact factor: 3.906

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.